Predicting Response to Neoadjuvant Chemotherapy Using Optical Tomographic Imaging in Women with Breast Cancer
Sponsor: |
Investigator initiated study |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAI0480 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study examines diffuse optical tomography (DOT) as a way to monitor the progress of the breast cancer therapy. Specifically, it looks at DOTs ability to detect non-responders early in treatment and then adjust the therapy to improve response and overall survival. DOT is favorable to more conventional forms of cancer monitoring, such as physical exams, mammograms, ultrasounds, and MRIs, because it can detect early changes to blood vessels that occur during tumor development. DOT is also less expensive and is less toxic as it does not use radiation.
This study is closed
Investigator
Dawn Hershman, MD
Are you a female over age 18 or older? |
Yes |
No |
Do you have breast cancer? |
Yes |
No |